Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
28.34
-1.52 (-5.09%)
At close: May 30, 2025, 4:00 PM
29.99
+1.65 (5.82%)
After-hours: May 30, 2025, 7:55 PM EDT
Company Description
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases.
It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.
Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency.
Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc.
Country | United States |
Founded | 2017 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Imran Alibhai |
Contact Details
Address: 3 Sugar Creek Center Boulevard, Suite 525 Sugar Land, Texas 77478 United States | |
Phone | 832-413-1362 |
Website | tvarditherapeutics.com |
Stock Details
Ticker Symbol | TVRD |
Exchange | NASDAQ |
Stock Type | Common Stock |
Reporting Currency | USD |
CIK Code | 0001742947 |
CUSIP Number | 140755307 |
ISIN Number | US1407553072 |
Key Executives
Name | Position |
---|---|
Dr. Imran Alibhai Ph.D. | Chief Executive Officer and Director |
Wallace Hall Jr. | Founder, President and Director |
David J. Tweardy M.D. | Co-Founder and Scientific Advisory Board Member |
Dr. Ronald A. DePinho M.D. | Co-Founder and Chairman of Scientific Advisory Board |
Dr. Michael T. Lewis Ph.D. | Co-Founder and Scientific Advisory Board Member |
Dan Conn J.D., M.B.A. | Chief Financial Officer |
Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of Research & Development |
Dr. John Kauh M.D. | Chief Medical Officer |
Stephen O'Brien CPA | Vice President of Finance and Corporate Controller |
Dr. Yixin Chen Ph.D. | Vice President of CMC |